Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fate reports Phase I data for Fate-NK100 in ovarian cancer

Fate Therapeutics Inc. (NASDAQ:FATE) reported data from two evaluable patients with ovarian cancer in the Phase

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE